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Abstract
Hepatitis B virus (HBV) infection can lead to serious liver diseases, including liver cirrhosis (LC) and hepatocellular carcinoma
(HCC); however, about 85–90% of infected individuals become inactive carriers with sustained biochemical remission and
very low risk of LC or HCC. To identify host genetic factors contributing to HBV clearance, we conducted genome-wide
association studies (GWAS) and replication analysis using samples from HBV carriers and spontaneously HBV-resolved
Japanese and Korean individuals. Association analysis in the Japanese and Korean data identified the HLA-DPA1 and HLA-
DPB1 genes with Pmeta= 1.89610
212 for rs3077 and Pmeta= 9.69610
210 for rs9277542. We also found that the HLA-DPA1 and
HLA-DPB1 genes were significantly associated with protective effects against chronic hepatitis B (CHB) in Japanese, Korean
and other Asian populations, including Chinese and Thai individuals (Pmeta= 4.40610
219 for rs3077 and Pmeta= 1.28610
215
for rs9277542). These results suggest that the associations between the HLA-DP locus and the protective effects against
persistent HBV infection and with clearance of HBV were replicated widely in East Asian populations; however, there are no
reports of GWAS in Caucasian or African populations. Based on the GWAS in this study, there were no significant SNPs
associated with HCC development. To clarify the pathogenesis of CHB and the mechanisms of HBV clearance, further studies
are necessary, including functional analyses of the HLA-DP molecule.
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Introduction
Overall, one-third of the world’s population (2.2 billion) is
infected with hepatitis B virus (HBV), and about 15% of these
are chronic carriers. About 75% of the chronic carriers live in
the east-south Asia and east pacific area, and there are 1.3–1.5
million chronic carriers living in Japan [1]. Of chronic carriers,
10–15% develop liver cirrhosis (LC), liver failure and hepato-
cellular carcinoma (HCC), and the remaining individuals
eventually achieve a state of nonreplicative infection, resulting
in hepatitis B surface antigen (HBsAg) negative and hepatitis B
core antibody (anti-HBc) positive, i.e. HBV-resolved individuals
[2–3]. In Japan, although the major route of HBV transmission
was perinatal transmission and horizontal transmission in early
childhood, infant HBV carriers have successfully been reduced
since 1986 through a selective vaccination policy by the
Japanese government [4–7]. However, the prevalence of HBV
genotype A in acute HBV (AHB) infection has increased
markedly since 2000, reaching approximately 52% in 2008 due
to the lack of a universal HB vaccination, and around 10% of
AHB cases could be persistent infection [8–9]. Viral factors, as
well as host factors, are thought to be associated with persistent
HB infection.
In 2009, significant associations between chronic hepatitis B
(CHB) and a region including HLA-DPA1 and HLA-DPB1 were
identified using 786 Japanese individuals having CHB and 2,201
control individuals through a two-stage genome-wide association
study (GWAS) [10]. The same group was also subjected to a
second GWAS using a total of 2,667 Japanese persistent HBV
infection cases and 6,496 controls, which confirmed significant
associations between the HLA-DP locus and CHB, in addition to
associations with another two SNPs located in the genetic region
including the HLA-DQ gene [11]. The associations between HLA-
DP variants with HBV infection were replicated in other Asian
populations, including Thai and Han Chinese individuals [10,12–
13]. With regard to HBV clearance, the association between the
human leukocyte antigen (HLA) class II allele and clearance of
HBV was confirmed by the candidate gene approach in African,
Caucasian and Asian populations [14–18]. However, in a previous
GWAS using samples of Japanese CHB and control individuals,
the clinical data on HBV exposure in the control individuals were
unknown, and this may have led to bias. Moreover, there have
been no reports of GWAS using samples from HBV carriers and
HBV-resolved individuals to identify host genetic factors associ-
ated with HBV clearance other than HLA class II molecules.
Here, we performed a GWAS using samples from Japanese
HBV carriers, healthy controls and spontaneously HBV-resolved
individuals in order to confirm or identify the host genetic factors
related to CHB and viral clearance. In the subsequent replication
analysis, we validated the associated SNPs in the GWAS using two
independent sets of Japanese and Korean individuals. In our
study, healthy controls were randomly selected with clinically no
evidence of HBV exposure, therefore, HBV-resolved individuals
were prepared to clearly identify the host genetic factors related
with CHB or HBV clearance.
Results
Protective Effects Against Chronic Hepatitis B in Japanese
and Korean Individuals
In this study, we conducted a GWAS using samples from 181
Japanese HBV carriers (including asymptomatic carriers (ASC),
CHB cases, LC cases and HCC cases, based on the criteria
described in Materials and Methods) and 184 healthy controls in
order to identify the host genetic factors related to progression of
CHB. All samples were genotyped using a genome-wide SNP
typing array (Affymetrix Genome-Wide Human SNP Array 6.0
for 900 K SNPs). Figure 1a shows a genome-wide view of the
single point association data based on allele frequencies using the
SNPs that met the following filtering criteria: (i) SNP call rate
$95%; (ii) minor allele frequency (MAF) $1% for HBV carriers
and healthy controls; and (iii) no deviation from Hardy-Weinberg
equilibrium (HWE) P$0.001 in healthy controls. We identified
significant associations of protective effects against CHB with two
SNPs (rs3077 and rs9277542) using the allele frequency model,
both of which are located in the 39 UTR of HLA-DPA1 and in the
sixth exon of HLA-DPB1, respectively (rs3077, P=1.1461027, and
rs9277542, P=5.3261028, respectively). The association for
rs9277542 reached a genome-wide level of significance in the
GWAS panel (Bonferroni criterion P,8.3661028 (0.05/
597,789)).
In order to validate the results of GWAS, a total of 32 SNPs,
including the associated two SNPs (rs3077 and rs9277542), were
selected for replication in two independent sets of HBV carriers
and healthy controls (replication-1:256 Japanese HBV carriers and
236 Japanese healthy controls; and replication-2:344 Korean
HBV carriers and 151 Korean healthy controls; Table 1). The
associations for the original significant SNP (rs9277542) and
marginal SNP (rs3077) on GWAS were replicated in both
replication sets [replication-1 (Japanese); rs3077, P=2.7061028,
OR =0.48 and rs9277542, P=3.3361026, OR =0.54; replica-
tion-2 (Korean); rs3077, P=2.0861026, OR =0.47 and
rs9277542, P=8.2961025, OR =0.54, Table 2]. We conducted
meta-analysis to combine these studies using the DerSimonian
Laird method (random effects model) to incorporate variation
among studies. As shown in Table 2, the odds ratios were quite
similar across the three studies (GWAS and two replication studies)
and no heterogeneity was observed (Phet=0.80 for rs3077 and 0.40
for rs9277542). Pmeta values were 4.40610
219 for rs3077 (OR
=0.46, 95% confidence interval (CI) = 0.39–0.54), and
1.28610215 for rs9277542 (OR =0.50, 95% CI= 0.43–0.60).
Among the remaining 30 SNPs in the replication study, 27 SNPs
were successfully genotyped by the DigiTag2 assay with SNP call
rate $ 95% and HWE p-value $ 0.01. Two SNPs (rs9276431 and
rs7768538), located in the genetic region including the HLA-DQ
gene, were marginally replicated in the two sets of HBV carriers
and healthy controls with Mantel-Haenszel P values of 2.8061027
(OR =0.56, 95% CI= 0.45–0.70) and 1.0961027 (OR =0.53,
95% CI= 0.42–0.67), respectively, when using additive, two-tailed
Cochran Mantel-Haenszel (CMH) fixed-effects model with no
evidence of heterogeneity (Phet=0.67 for rs9276431 and 0.70 for
rs7768538) (Table S1).
Meta-analysis using the random effects model across 6
independent studies, including 5 additional published data,
showed Pmeta=3.94610
245, OR =0.55 for rs3077,
Pmeta=1.74610
221, OR =0.61 for rs9277535 and
Pmeta=1.69610
215, OR =0.51 for rs9277542, with the SNP
rs9277535 being located about 4-kb upstream from rs9277542 and
showing strong linkage disequilibrium of r2 = 0.955 on the
HapMap JPT (Table S2). As shown in Table S2, the odds ratio
was very similar among the 6 studies, and heterogeneity was
negligible with Phet .0.01.
Moreover, based on GWAS using samples from 94 chronic
HBV carriers with LC or HCC and 87 chronic HBV carriers
without LC and HCC, we found no significant SNPs associated
with CHB progression (Figure S1).
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Clearance of Hepatitis B virus in Japanese and Korean
Individuals
We also conducted a GWAS to identify the host genetic factors
related to clearance of HBV in the above 181 Japanese HBV
carriers and 185 Japanese HBV-resolved individuals using a
genome-wide SNP typing array (Affymetrix Genome-Wide
Human SNP Array 6.0 for 900 K SNPs). The same two SNPs
(rs3077 and rs9277542) showed strong associations in the allele
frequency model (P=9.2461027 and P=3.1561025) with clear-
ance of HBV (Figure 1b).
The above 32 SNPs, including the two associated SNPs (rs3077
and rs9277542), were selected for a replication study in two
independent sets of HBV carriers and HBV resolved individuals
(replication-1:256 Japanese HBV carriers and 150 Japanese HBV
resolved individuals; and replication-2:344 Korean HBV carriers
and 106 Korean HBV resolved individuals; Table 1). All 32 SNPs
were genotyped using the DigiTag2 assay and 29 of 32 SNPs were
successfully genotyped (Table S3). The associations of the original
SNPs were replicated in both replication sets [replication-1
(Japanese): rs3077, P=3.3261022, OR =0.72 and rs9277542,
P=1.2561022, OR =0.68; replication-2 (Korean): rs3077,
P=2.3561027, OR =0.41 and rs9277542, P=4.9761026, OR
=0.46; Table 3]. Meta-analysis using random effects model
showed Pmeta=1.56610
24 for rs3077 (OR =0.51, 95%
CI= 0.36–0.72), and 5.9161027 for rs9277542 (OR =0.55,
95% CI= 0.43–0.69). While there was evidence of heterogeneity
between these studies for rs3077 (Phet = 0.03) and no evidence for
rs9277542 (Phet = 0.19), significant associations with HBV clear-
ance were observed with Mantel-Haenszel Pmeta=3.28610
212 for
rs3077 and 1.42610210 for rs9277542, when using CMH fixed-
effects model. Among the remaining 27 SNPs in the replication
study, two SNPs (rs9276431 and rs7768538), located in a genetic
region including HLA-DQ gene, were marginally replicated in the
two sets of HBV carriers and HBV resolved individuals with
Mantel-Haenszel P values of 2.1061025 (OR =0.59) and
1.1061025 (OR =0.56), respectively (Table S3), when using
CMH fixed-effect model. Due to the existing heterogeneity among
three groups (GWAS, Replication-1 and Replication-2) (Phet=0.03
for rs9276431 and 0.04 for rs7768538), weak associations were
observed with Pmeta=0.03 for rs9276431 and 0.02 for rs7768538
by the random effects model meta-analysis.
Meta-analysis across 6 independent studies, including 5
additional published data, showed Pmeta=1.48610
29, OR
=0.60 for rs3077, Pmeta=1.08610
217, OR =0.66 for rs9277535
and Pmeta=5.14610
25, OR =0.55 for rs9277542 (Table S4). As
shown in Table S4, the OR for the rs9277535 and rs9277542 were
similar among the 6 independent studies, and heterogeneity was
negligible (Phet=0.03 for rs9277535 and 0.14 for rs9277542).
However, significant level of heterogeneity for rs3077 was
observed with Phet=9.57610
26 across 5 independent studies,
including our study.
URLs
The results of the present GWAS are registered at a public database:
https://gwas.lifesciencedb.jp/cgi-bin/gwasdb/gwas_top.cgi.
Discussion
The recent genome-wide association study showed that the
SNPs located in a genetic region including HLA-DPA1 and HLA-
DPB1 genes were associated with chronic HBV infection in the
Japanese and Thai population [10,11]. In this study, we confirmed
a significant association between SNPs (rs3077 and rs9277542)
located in the same genetic region as HLA-DPA1 and HLA-DPB1
and protective effects against CHB in Korean and Japanese
individuals. Mata-analysis using the random effects model across 6
independent studies including our study suggested that, widely in
East Asian populations, variants in antigen binding sites of HLA-
DP contribute to protective effects against persistent HBV
infection (Table S2).
On GWAS and replication analysis with Japanese and Korean
individuals, we identified associations between the same SNPs
(rs3077 and rs9277542) in the HLA-DPA1 and HLA-DPB1 genes
and HBV clearance; however, no new candidate SNPs from the
GWAS were detected on replication analysis (Table S3). When the
data of reference#18 was excluded from the meta-analysis across
6 independent studies, heterogeneity among 4 studies was
estimated to be Phet=0.15 and significant association of rs3077
with HBV clearance was observed with Pmeta=5.88610
224, OR
=0.56 (Table S4). In our study, a negligible level of heterogeneity
for rs3077 was also observed (Phet=0.03) on meta-analysis by
adding replication-1 (Table 3). Despite the heterogeneity in
replication-1, a marginal association was observed for rs3077 with
the same downward trend in the odds ratio (P=3.3261022, OR
=0.72). Moreover, meta-analysis using GWAS and replication-2
showed significant association of Pmeta=1.89610
212, OR =0.43
for rs3077 with no evidence of heterogeneity (Phet=0.75).
Although the reason why heterogeneity was observed in replica-
tion-1 is unclear, one possible reason is the clinical heterogeneity
due to different kits being used for antibody testing. The
associations of HLA-DPA1/2DPB1 with CHB and HBV clearance
showed the same level of significance in the comparison of HBV
patients with HBV resolved individuals (OR =0.43 for rs3077 and
0.49 for rs9277542) as the one with healthy controls (OR =0.46
for rs3077 and 0.50 for rs9277542), when the replication-1 was
excluded in the analysis (Table 2 and Table 3). The results of
meta-analysis across 6 independent studies including our study
also showed the same or slightly weaker associations in the
Figure 1. Results of genome-wide association studies. a) HBV carriers and healthy controls, and b) HBV carriers and HBV-resolved individuals
were compared. P values were calculated by chi-squared test for allele frequencies. Dots with arrows on chromosome 6 show strong associations
with protective effects against persistent HB infection and with HBV clearance.
doi:10.1371/journal.pone.0039175.g001
Table 1. Number of study samples.
GWAS Replication-1 Replication-2
population Japanese Japanese Korean
HBV carriers Total 181 256 344
IC 20 94 –
CH 67 101 177
LC 3 10 –
HCC 91 51 167
Healthy controls 184 236 151
Resolved individuals 185 150 106
Abbreviation: IC, Inactive Carrier; CH, Chronic Hepatitis; LC, Liver Cirrhosis; HCC,
Hepatocellular Carcinoma.
doi:10.1371/journal.pone.0039175.t001
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comparison of HBV patients with HBV resolved individuals (OR
=0.56 for rs3077, 0.66 for rs9277535 and 0.55 for rs9277542)
than in the one with healthy controls (OR =0.55 for rs3077, 0.61
for rs9277535 and 0.51 for rs9277542), which was the opposite
result as we expected (Table S2 and Table S4). These results may
suggest that other unknown immune system(s) exist to eliminate
the HBV in the HBV resolved individuals.
Among the HLA class II loci (HLA-DPA1, HLA-DPB1 and HLA-
DQB2), which were associated with CHB and HBV clearance, a
weak linkage disequilibrium (r2,0.1) was observed between HLA-
DQB2 locus and HLA-DPA1/2DPB1 loci in Japanese and Korean
populations (Figure S2). We also found that similar linkage
disequilibrium blocks (r2) were observed among three subgroups
(HBV carriers, HBV resolved individuals and Healthy controls).
Moreover, logistic regression analysis of HLA-DP (rs3077 and
rs92775542) with use of HLA-DQ (rs9276431 and rs768538) as
covariates showed that the same level of significant associations of
HLA-DP with CHB and HBV clearance as shown in the single-
point association analysis, while no associations of HLA-DQ with
Plog .0.05 were detected both in Japanese and in Korean (Table
S5). These results show that HLA-DP is the main genetic factor for
susceptibility to CHB and HBV clearance, and the associations of
HLA-DQB2 would result from linkage disequilibrium of HLA-
DPA1/2DPB1.
In this study, we confirmed the significant associations between
HLA-DPA1 and HLA-DPB1, and protective effects against CHB
and HBV clearance in Japanese and Korean individuals. These
results suggest that the associations between the HLA-DP locus,
CHB and HBV clearance are widely replicated in East Asian
populations, including Chinese, Thai, Japanese and Korean
individuals; however, there have been no similar GWAS
performed in Caucasian and African populations. Moreover,
there were no significant SNPs associated with HCC development
in this study, thus suggesting that it is necessary to increase the
sample size. To clarify the pathogenesis of CHB or the
mechanisms of HBV clearance, further studies are necessary,
including a functional study of the HLA-DP molecule, identifica-
tion of novel host genetic factors other than HLA-DP, and
variation analysis of HBV.
Materials and Methods
Ethics Statement
All study protocols conform to the relevant ethical guidelines, as
reflected in the a priori approval by the ethics committees of all
participating universities and hospitals. The written informed
consent was obtained from each patient who participated in this
study and all samples were anonymized.
Genomic DNA Samples and Clinical Data
All of the 1,793 Japanese and Korean samples, including
individuals with CHB, healthy controls and HBV-resolved
individuals (HBsAg-negative and anti-HBc-positive), were col-
lected at 20 multi-center hospitals (liver units with hepatologists)
throughout Japan and Korea. The 19 hospitals in Japan were
grouped into the following 8 areas: Hokkaido area (Hokkaido
University Hospital, Teine Keijinkai Hospital), Tohoku area
(Iwate Medical University Hospital), Kanto area (Musashino Red
Cross Hospital, Saitama Medical University, Kitasato University
Hospital, University of Tokyo), Koshin area (Shinshu University
Hospital, Kanazawa University Hospital), Tokai area (Nagoya
City University Hospital, Nagoya Daini Red Cross Hospital),
Kinki area (Kyoto Prefectural University of Medicine Hospital,
National Hospital Organization Osaka National Hospital, Osaka
Table 2. Results of replication study for protective effects against CHB.
Position MAFa Allele Stage HBV carriers Healthy controls ORb
dbSNP rsID Chr Buld 36.3 Nearest Gene (allele) (1/2) (population) 11 12 22 11 12 22 HWEp 95% CI P-valuec Phet
d
rs3077 6 33141000HLA-DPA1 0.44 T/C GWAS 13 51 117 28 88 67 0.919 0.42 1.1461027
(T) (Japanese) (7.2) (28.2) (64.6) (15.3) (48.1) (36.6) (0.30–0.58)
Replication-1 26 95 134 46 125 65 0.309 0.48 2.7061028
(Japanese) (10.2) (37.3) (52.5) (19.5) (53.0) (27.5) (0.37–0.62)
Replication-2 23 81 111 31 74 40 0.767 0.47 2.0861026
(Korean) (10.7) (37.7) (51.6) (21.4) (51.0) (27.6) (0.35–0.65)
Meta-analysise 0.46 4.40610219 0.80
(0.39–0.54)
rs9277542 6 33163225HLA-DPB1 0.45 T/C GWAS 18 53 110 29 102 52 0.073 0.42 5.3261028
(T) (Japanese) (9.9) (29.3) (60.8) (15.8) (55.7) (28.4) (0.31–0.58)
Replication-1 30 106 118 54 114 67 0.681 0.54 3.3361026
(Japanese) (11.8) (41.7) (46.5) (23.0) (48.5) (28.5) (0.42–0.70)
Replication-2 30 87 94 35 72 36 0.933 0.54 8.2961025
(Korean) (14.2) (41.2) (44.5) (24.5) (50.3) (25.2) (0.40–0.74)
Meta-analysise 0.50 1.28610215 0.40
(0.43–0.60)
aMinor allele frequency and minor allele in 198 healthy Japanese (ref#19).
bOdds ratio of minor allele from two-by-two allele frequency table.
cP value of Pearson’s chi-square test for allelic model.
dHeterogeneity was tested using general variance-based method.
eMeta-analysis was tested using the random effects model.
doi:10.1371/journal.pone.0039175.t002
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City University), Chugoku/Shikoku area (Tottori University
Hospital, Ehime University Hospital, Yamaguchi University
Hospital, Kawasaki Medical College Hospital) and Kyushu area
(Kurume University Hospital). Korean samples were collected at
Yonsei University College of Medicine.
HBV status was measured based on serological results for
HBsAg and anti-HBc with a fully automated chemiluminescent
enzyme immunoassay system (Abbott ARCHITECT; Abbott
Japan, Tokyo, Japan, or LUMIPULSE f or G1200; Fujirebio,
Inc., Tokyo, Japan). For clinical staging, inactive carrier (IC) state
was defined by the presence of HBsAg with normal ALT levels
over 1 year (examined at least four times at 3-month intervals) and
without evidence of portal hypertension. Chronic hepatitis (CH)
was defined by elevated ALT levels (.1.5 times the upper limit of
normal [35 IU/L]) persisting over 6 months (at least by 3
bimonthly tests). Liver cirrhosis (LC) was diagnosed principally by
ultrasonography (coarse liver architecture, nodular liver surface,
blunt liver edges and hypersplenism), platelet counts ,100,000/
cm3, or a combination thereof. Histological confirmation by fine-
needle biopsy of the liver was performed as required. Hepatocel-
lular carcinoma (HCC) was diagnosed by ultrasonography,
computerized tomography, magnetic resonance imaging, angiog-
raphy, tumor biopsy or a combination thereof.
The Japanese control samples from HBV-resolved subjects
(HBsAg-negative and anti-HBc-positive) at Nagoya City Universi-
ty-affiliated healthcare center were used by comprehensive agree-
ment (anonymization in an unlinkable manner) in this study. Some
of the unrelated Japanese healthy controls were obtained from the
Japan Health Science Research Resources Bank (Osaka, Japan).
One microgram of purified genomic DNA was dissolved in 100 ml
of TE buffer (pH 8.0) (Wako, Osaka, Japan), followed by storage at
220uC until use.
SNP Genotyping and Data Cleaning
For GWAS, we genotyped a total of 550 individuals, including
181 Japanese HBV carriers, 184 Japanese healthy controls and
185 spontaneously HBV-resolved Japanese individuals (HBsAg-
negative and anti-HBc-positive), using the Affymetrix Genome-
Wide Human SNP Array 6.0 (Affymetrix, Inc., Santa Clara, CA),
in accordance with the manufacturer’s instructions. The average
QC call rate for 550 samples reached 98.47% (95.00–99.92%),
which had an average sample call rate of 98.91% (93.55–99.74%)
by determining the genotype calls of over 900 K SNPs using the
Genotyping Console v4.1 software (with Birdseed v1 algorithm)
provided by the manufacturer [19]. We then applied the following
thresholds for SNP quality control in data cleaning: SNP call rate
$95% and MAF $1% for three groups (HBV carriers, healthy
controls and HBV-resolved individuals), and HWE P-value
$0.001 for healthy controls [20]. Here, SNP call rate is defined
for each SNP as the number of successfully genotyped samples
divided by the number of total samples genotyped. A total of
597,789 SNPs and 590,278 SNPs on autosomal chromosomes
Table 3. Results of replication study for clearance of hepatitis B virus.
Position MAFa Allele Stage HBV carriers Resolved individuals ORb
dbSNP rsID Chr Buld 36.3 Nearest Gene (allele) (1/2) (population) 11 12 22 11 12 22 95% CI P-valuec Phet
d
rs3077 6 33141000HLA-DPA1 0.44 T/C GWAS 13 51 117 29 82 74 0.44 9.2461027
(T) (Japanese) (7.2) (28.2) (64.6) (15.7) (44.3) (40.0) (0.32–0.61)
Replication-1 26 95 134 20 64 60 0.72 3.3261022
(Japanese) (10.2) (37.3) (52.5) (13.9) (44.4) (41.7) (0.53–0.97)
Replication-2 23 81 111 29 48 28 0.41 2.3561027
(Korean) (10.7) (37.7) (51.6) (27.6) (45.7) (26.7) (0.29–0.58)
Meta-analysise 0.51 1.5661024 0.03
(0.36–0.72)
Meta-analysise 0.43 1.89610212 0.75
(GWAS+replication-
2)
(0.34–0.54)
rs9277542 6 33163225HLA-DPB1 0.45 T/C GWAS 18 53 110 28 88 69 0.51 3.1561025
(T) (Japanese) (9.9) (29.3) (60.8) (15.1) (47.6) (37.3) (0.37–0.70)
Replication-1 30 106 118 28 62 52 0.68 1.2561022
(Japanese) (11.8) (41.7) (46.5) (19.7) (43.7) (36.6) (0.51–0.92)
Replication-2 30 87 94 30 53 22 0.46 4.9761026
(Korean) (14.2) (41.2) (44.5) (28.6) (50.5) (21.0) (0.33–0.64)
Meta-analysise 0.55 5.9161027 0.19
(0.43–0.69)
Meta-analysise 0.49 9.69610210 0.65
(GWAS+replication-
2)
(0.39–0.61)
aMinor allele frequency and minor allele in 198 healthy Japanese (ref#19).
bOdds ratio of minor allele from two-by-two allele frequency table.
cP value of Pearson’s chi-square test for allelic model.
dHeterogeneity was tested using general variance-based method.
eMeta-analysis was tested using the random effects model.
doi:10.1371/journal.pone.0039175.t003
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passed the quality control filters in the genome-wide association
analysis using HBV carriers and healthy controls, and using HBV
carriers and HBV-resolved individuals, respectively (Figure 1). All
cluster plots for the SNPs showing P,0.0001 on association
analyses in the allele frequency model were confirmed by visual
inspection, and SNPs with ambiguous cluster plots were excluded.
In the following replication stage, we selected a set of 32 SNPs
with P,0.0001 in the GWAS using HBV carriers and HBV-
resolved individuals. SNP genotyping in two independent sets of
256 Japanese HBV carriers, 236 Japanese healthy controls and
150 Japanese HBV-resolved individuals (Table 1, replication-1),
and 344 Korean HBV carriers, 151 Korean healthy controls and
106 Korean HBV-resolved individuals (Table 1, replication-2) was
completed for the selected 32 SNPs using the DigiTag2 assay
[21,22] and custom TaqMan SNP Genotyping Assays (Applied
Biosystems, Foster City, CA) on the LightCycler 480 Real-Time
PCR System (Roche, Mannheim, Germany).
Statistical Analysis
The observed associations between SNPs and the protective
effects on chronic hepatitis B or clearance of hepatitis virus B were
assessed by chi-squared test with a two-by-two contingency table
in allele frequency model. SNPs on chromosome X were removed
because gender was not matched among HBV carriers, healthy
controls and HBV-resolved individuals. A total of 597,789 SNPs
and 590,278 SNPs passed the quality control filters in the GWAS
stage; therefore, significance levels after Bonferroni correction for
multiple testing were P=8.3661028 (0.05/597,789) and
P=8.4761028 (0.05/590,278), respectively. For the replication
study, 29 of 32 SNPs were successfully genotyped; therefore, we
applied P=0.0017 (0.05/29) as a significance level, and none of
the 29 markers genotyped in the replication stage showed
deviations from the Hardy-Weinberg equilibrium in healthy
controls (P.0.01).
The genetic inflation factor l was estimated by applying the
Cochrane-Armitage test on all SNPs and was found to be 1.056
and 1.030 in the GWAS using HBV carriers and healthy controls,
and using HBV carriers and HBV-resolved individuals, respec-
tively (Figure S3). These results suggest that the population
substructure should not have any substantial effect on statistical
analysis. In addition, the principal component analysis in a total of
550 individuals in the GWAS stage together with the HapMap
samples also revealed that the effect of population stratification
was negligible (Figure S4).
Based on the genotype data of a total of 1,793 samples including
1,192 Japanese samples and 601 Korean samples in both GWAS
and replication stages, haplotype blocks were estimated using the
Gabriel’s algorithm using the Haploview software (v4.2) (Figure
S2). In the logistic regression analysis, two SNPs (rs9276431 and
rs7768538) within the HLA-DQ locus were individually involved
as a covariate (Table S5). Statistical analyses were performed using
the SNP & Variation Suite 7 software (Golden Helix, MT, USA).
Supporting Information
Figure S1 GWAS using samples from HBV carriers with
LC or HCC, and HBV carriers without LC and HCC. P
values were calculated using chi-squared test for allele frequencies.
(PPTX)
Figure S2 Estimation of linkage disequilibrium blocks
in HBV patients, HBV resolved individuals and healthy
controls in Japanese and Korean. The LD blocks (r2) were
analyzed using the Gabriel’s algorithm.
(PPTX)
Figure S3 Quantile-quantile plot for test statistics
(allele-based chi-squared tests) for GWAS results. Dots
represent P values of each SNP that passed the quality control
filters. Inflation factor l was estimated to be: a) 1.056 in the
analysis with HBV carriers and healthy controls; and b) 1.030 with
HBV carriers and HBV-resolved individuals.
(PPTX)
Figure S4 Principal component analysis on a total of
550 individuals in GWAS, together with HapMap
samples (CEU, YRI and JPT).
(PPTX)
Table S1 Results for 29 SNPs selected in replication
study using samples of HBV carriers and healthy
controls. aP values by chi-squared test for allelic model. bOdds
ratio of minor allele from two-by-two allele frequency table.
cMeta-analysis was tested using additive, two-tailed CMH fixed-
effects model.
(XLSX)
Table S2 Results of meta-analysis for protective effects
against persistent HB infection across 6 independent
studies, including this study. aMinor allele frequency and
minor allele in 198 healthy Japanese (ref#19). bOdds ratio of
minor allele from two-by-two allele frequency table. cP value of
Pearson’s chi-squared test for allele model. dHeterogeneity was
tested using general variance-based method. eMeta-analysis was
tested using the random effects model.
(XLSX)
Table S3 Results for 29 SNPs selected in replication
study using samples from HBV carriers and HBV-
resolved individuals. aP values by chi-squared test for allelic
model. bOdds ratio of minor allele from two-by-two allele
frequency table. cMeta-analysis was tested using additive, two-
tailed CMH fixed-effects model.
(XLSX)
Table S4 Results of meta-analysis for clearance of HBV
across 6 independent studies, including this study.
aMinor allele frequency and minor allele in 198 healthy Japanese
(ref#19). bOdds ratio of minor allele from two-by-two allele
frequency table. cP value of Pearson’s chi-squared test for allele
model. dHeterogeneity was tested using general variance-based
method. eMeta-analysis was tested using the random effects model.
(XLSX)
Table S5 Logistic regression analysis of HLA-DP
(rs3077 and rs9277542) and HLA-DQ (rs9276431 and
rs7768538) with susceptibility to CHB and HBV clear-
ance using the HLA-DQ genotypes individually as a
covariate.
(XLSX)
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